cabazitaxel / Generic mfg. - LARVOL DELTA

Enhanced therapeutics of cabazitaxel via polycarboxylate conjugation: improved solubility, safety, and antitumor efficacy. (PubMed, Front Immunol) - "Pharmacokinetic analysis showed prolonged circulation, efficient clearance, and drastically diminished off-target tissue accumulation for CTX-DTPA. This study establishes polycarboxylate conjugation as a promising strategy for developing safer and more effective chemotherapeutic agents through rational molecular design, successfully decoupling antitumor efficacy from systemic toxicity."

Journal • Oncology

Biocompatible sulfonium-based covalent probes for endogenous tubulin fluorescence nanoscopy in live and fixed cells. (PubMed, Nat Commun) - "Using cabazitaxel as a tubulin targeting moiety and silicon-rhodamine as a cell permeable fluorophore, we designed and optimized probe, 6-SiR-o-C9-CTX, containing a biocompatible cleavable linker with a sulfonium center...Importantly, taxane targeting moiety can be removed post-labeling, preserving tubulin's functions. This labeling strategy is compatible with STED nanoscopy in both live and fixed cells, enabling high-resolution, minimally invasive cytoskeletal imaging, and advancing the toolkit for studying dynamic cellular processes."

Journal

Enhanced Efficacy and Safety: Cabazitaxel Nanodispersions as a Novel Therapeutic Platform against Prostate Cancer. (PubMed, AAPS PharmSciTech) - "The pharmacokinetic studies in rats revealed that, compared to CTX-TW, CTX-NP had an extended half-life (T1/2), mean residence time (MRT), and a larger area under the drug concentration-time curve (AUC). In the RM-1 prostate cancer mouse model, compared with CTX-TW, the high-dose CTX-NP group showed better tumor inhibition with an inhibition rate of 79.48%, indicating that CTX-NP could achieve superior anti-tumor effects by increasing the administered dose."

Journal • Genito-urinary Cancer • Hematological Disorders • Oncology • Prostate Cancer • Solid Tumor

Monoamine neurotransmitter functionalized poly(amidoamine) dendrimers for targeting of cabazitaxel to human prostate cancer cells. (PubMed, Discov Nano) - "According to the findings, CBZ@PEG-DEND showed significantly higher time- and dose-dependent cytotoxicities and growth-inhibitory effects to DU145 cells in comparison to pure CBZ. Further, the cellular uptake studies revealed high cellular uptake of targeted and fluorescent conjugate (Rho@ST-PEG-DEND) in comparison to non-targeted fluorescent conjugate (Rho@PEG-DEND), highlighting the role of ST in improved delivery of CBZ to 5HT receptor overexpressed cancer cells."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Identification of osteoarthritis-related genes and potential drugs based on single cell RNA-seq data. (PubMed, Mol Med) - "The RT-qPCR results of zebrafish verified that Pitavastatin inhibited the expression of HMGCR, while Cabazitaxel inhibited the expression of TUBB1. Our study suggested that Pitavastatin has therapeutic effects on OA, while Cabazitaxel increases the risk of OA."

Journal • Cardiovascular • Genito-urinary Cancer • Immunology • Oncology • Osteoarthritis • Pain • Prostate Cancer • Rheumatology • Solid Tumor • BIRC3 • CCL20 • CXCL8 • ICAM1 • MMP3 • TUBB1

Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer. (PubMed, JCI Insight) - P4 | "This preplanned biomarker analysis of CARD confirms that CTC-CIN counts are a clinically useful prognostic and predictive biomarker of taxane resistance in mCRPC. Detectable CTC-CIN at baseline defines a patient subpopulation with unmet clinical needs in which alternative therapeutics should be tested."

Circulating tumor cells • Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CTCs

Effect of TGF-β mediated phenotypic changes on prostate cancer cell anoikis response. (PubMed, Oncogene) - "We assessed their response to TGF-β (EMT inducer) and two antitumor agents (DZ-50 and cabazitaxel (CBZ)) to understand the effect of EMT priming on anoikis vulnerability...TGF-β induced EMT further sensitizes LNCaPTβRII to DZ-50 induced anoikis. DZ-50-associated anoikis cell death in prostate cancer cells is associated with (i) phenotypic reprogramming (EMT to mesenchymal epithelial transition (MET)) (ii) inactivation of SRC (decreased pSRC) (iii) decreased cofilin expression in LNCaPTβRII and VCaP cells."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • TGFB1

Real-World Treatment Patterns and Overall Survival (OS) of Patients with Metastatic Castration-Resistant Prostate Cancer in Italy. (PubMed, Pragmat Obs Res) - "mCRPC was proxied by treatment patterns-addition of docetaxel/cabazitaxel or ARPI to ADT-and confirmed by hospital discharge for metastasis. While OS from ADT initiation has improved, survival from mCRPC diagnosis-based on proxies in administrative data-remains poor, underscoring an unmet clinical need. Differences in OS estimates depending on the starting point (ADT initiation vs mCRPC diagnosis) should be considered when interpreting results."

HEOR • Journal • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Albumin conjugated with WQPDTAHHWATL and GRFLTGGTGRLLRIS peptide improves targeted docetaxel delivery for prostate cancer: an in-silico approach. (PubMed, Res Pharm Sci) - "Anti-prostate cancer drugs such as docetaxel, doxorubicin, and cabazitaxel have drawbacks resulting from their low solubility, non-targeted transfer, and many side effects. Additionally, the C-terminus and N-terminus of the engineered albumin could bind to the PSMA receptor. It can be concluded that this engineered albumin is useful for targeted drug delivery in prostate cancer."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Overcoming Barriers to Cabazitaxel and Optimizing Sequencing (OncLive) - "Evidence-based approaches to cabazitaxel use in mCRPC, addressing treatment sequencing after prior therapies, real-world underutilization trends, patient counseling on benefits and risks, and FDA guidance on dosing strategies to optimize outcomes while managing toxicity."

Video

Cabazitaxel Sustained-Release Nanoparticles Treat Spinal Cord Injury through Inhibiting Fibrin Deposition and Improving the Microenvironment. (PubMed, Biomacromolecules) - "Evaluations based on electrophysiological assessments, Basso, Beattie, and Bresnahan (BBB) scores, and bladder function recovery revealed the nanoparticles' remarkable therapeutic efficacy in SCI. Therefore, biomaterials can facilitate axonal regeneration, tissue remodeling, and functional restoration following injury."

Journal • CNS Disorders • Orthopedics

CYP11A1 INHIBITOR OPEVESOSTAT ALONE OR IN COMBINATION WITH OTHER THERAPIES FOR PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: THE PHASE 1/2 OMAHA-01A SUBSTUDY (SUO 2025) - P1/2 | "In the efficacy phase, participants will be randomized 1:1:1:1 to receive opevesostat alone (5 mg PO BID; N≤100), or in combination with olaparib, docetaxel or cabazitaxel at the RP2D (~40 participants each). Secondary end points include ORR, DOR and radiographic PFS per PCWG-modified RECIST v1.1, and OS. "

Combination therapy • Metastases • P1/2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

ARPI doublet in mHSPC may negatively impact Cabazitaxel outcomes (EMUC 2025) - "Introduction & Objectives Cabazitaxel remains a key life-prolonging therapy for mCRPC, particularly after progression on ARPIs and docetaxel. Proactive toxicity management, including planned dose reductions and G-CSF prophylaxis, enables sustained therapy without loss of efficacy. These findings underscore the need for individualized sequencing and supportive care strategies to optimize cabazitaxel use in advanced prostate cancer."

Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Prostate Cancer • Solid Tumor

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (clinicaltrials.gov) - P1/2 | N=220 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Mar 2028 ➔ Jan 2029 | Trial primary completion date: Mar 2028 ➔ Jan 2029

Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Prognostic Accuracy and Clinical Effectiveness of 68Ga-PSMA-11 PET/CT (ILLUCIX®) Imaging Followed by 177-Lu-PSMA-617 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Literature Review (ISPOR-EU 2025) - "This review supports the theranostic approach of using ⁶⁸Ga-PSMA-11 PET/CT imaging to identify suitable candidates for PSMA-targeted radioligand therapy and to enable accurate assessment of treatment response. While direct evidence of imaging-related health outcomes is lacking, downstream improvements in clinical outcomes with ¹⁷⁷Lu-PSMA-617 validate the utility of this imaging-guided treatment strategy in mCRPC."

Clinical • Metastases • Review • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Cost Utility of Lu-PSMA Therapy: A Systematic Literature Review (ISPOR-EU 2025) - "Notably, some of the full economic evaluations published in countries like Canada lacked essential data typically required in economic evaluations, thereby limiting the interpretability of their findings"

HEOR • Review • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Solid Tumor

Cost-Effectiveness Analysis of Ga-PSMA-11 PET/CT Imaging Followed by Lu-PSMA-617 vs. Standard of Care in Metastatic Castrate-Resistant Prostate Cancer (ISPOR-EU 2025) - "This study evaluates cost-effectiveness of 68Ga-PSMA-11 PET/CT imaging followed by 177Lu-PSMA-617 therapy compared to cabazitaxel or best supportive care (BSC) without 68Ga-PSMA-11 PET/CT, in patients with metastatic castrate resistant prostate cancer (mCRPC) from Australian healthcare perspective. A cost-utility model was developed using hybrid approach: a decision tree to identify patients eligible for 177Lu-PSMA-617 therapy (those testing PSMA positive in 68Ga-PSMA-11 PET/CT imaging), followed by three-state partitioned survival model (PSM) over a 10-year time horizon. 68Ga-PSMA-11 PET/CT imaging followed by 177Lu-PSMA-617 offers improved clinical outcomes over standard of care. Integrating radiotracers such as 68Ga-PSMA-11 into PET/CT for early detection of metastatic disease enables more precise, targeted treatment and may help avoid unnecessary local radiotherapy."

Cost effectiveness • HEOR • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Cost-Utility Analysis of Lu-PSMA Therapy Compared to Taxane-Based Cabazitaxel in Patients Diagnosed With Metastatic Castration-Resistant Prostate Cancer: A Colombian Health System Perspective (ISPOR-EU 2025) - "Both therapies exceed the cost-utility threshold in Colombia; however, 177Lu-PSMA is associated with higher QALY gains. Strategies should be explored to facilitate the adoption of this radiopharmaceutical within the Colombian healthcare system."

Clinical • HEOR • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

PCPro as a prognostic plasma lipidomic biomarker in TheraP (ANZUP 1603): A randomised trial of [177Lu]Lu-PSMA-617 (LuPSMA) vs cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) (ESMO 2025) - P2 | "Background TheraP showed that LuPSMA improves PSA response rate (RR), objective tumour RR, and radiographic progression free survival (rPFS), compared with cabazitaxel in participants (pts) with PSMA-positive, non-FDG-discordant mCRPC progressing after docetaxel. Table: 2392P Multivariable analysis for OS Variable Hazard ratio [95% Confidence interval] p-value PCPro, positive 1.78 [1.05 – 3.03] 0.032 PSMA PET SUV mean 30% 4.07 [1.55 – 10.7] 8.91 [3.17 – 25.1] 0.004 <0.001 Conclusions PCPro positive status was an independently significant prognostic factor for shorter OS in pts treated with either LuPSMA or cabazitaxel in TheraP. These data support further research of PCPro as a prognostic biomarker in mCRPC being treated with LuPSMA or a taxane."

Biomarker • Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Plasma lipidomics and PCPro as prognostic biomarkers in TheraP (ANZUP 1603): a randomised trial of [177Lu]Lu-PSMA-617 (LuPSMA) vs cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) (PCF 2025) - "Background : The TheraP trial demonstrated that LuPSMA improved PSA response rates and radiographic progression-free survival (rPFS) compared to cabazitaxel in participants with PSMA- positive, non-FDG-discordant mCRPC progressing post docetaxel. PCPro-positive status is an independent prognostic factor for shorter OS in mCRPC patients treated with LuPSMA or cabazitaxel. Conversion from PCPro-positive to negative is associated with improved outcomes, suggesting that dynamic lipidomic changes may reflect treatment response. These findings highlight sphingolipid metabolism as a potential therapeutic target in treatment-resistant mCRPC."

Biomarker • Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Investigating access to 177LuPSMA-617 in metastatic castration-resistant prostate cancer (mCRPC) in France: comparative analysis with cabazitaxel using national hospital data (ESMO 2025) - "Further investigations are needed to better understand barriers and enablers influencing RLT access. Legal entity responsible for the study The authors."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer. (PubMed, BJU Int) - "Multi-line BST is feasible and can yield durable bladder preservation and oncological control in select patients with HR-NMIBC following BCG failure. Progression-free outcomes remained favourable across successive lines of salvage therapy. These findings support the role of longitudinal BST as an alternative to radical cystectomy in carefully and appropriately selected patients."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Real-world treatment patterns in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitor (ARPI) or docetaxelProstACT Global: A phase 3 study of Lutetium (Lu177) rosopatamab tetraxetan plus standard of care vs standard of care alone in patients with metastatic castration-resistant prostate cancer (PCF 2025) - "BACKGROUND: Patients with mCRPC whose disease progressed on an ARPI have a poor prognosis, with median overall survival of <2 years (Sayegh, Eur Urol Focus 2023). These real-world data show that ARPIs remain the most common 1L and 2L treatment in patients with mCRPC despite prior ARPI and/or docetaxel alongside androgen deprivation therapy for mHSPC or nmCRPC. TABLE. Treatment regimens by line of therapy in patients with mCRPC 1L regimen (N=510), 2L regimen (N=188), 3L regimen (N=80), n (%) n (%) n (%) ARPI*,† 289 (56.7) ARPI*,† 83 (44.1) Taxane‡ 23 (28.8) Abiraterone 149 (29.2) Abiraterone 35 (18.6) ARPI*,† 21 (26.3) Enzalutamide 124 (24.3) Enzalutamide 34 (18.1) Enzalutamide 10 (12.5) Taxane‡ 86 (16.9) Taxane‡ 50 (26.6) Abiraterone 8 (10.0) Abiraterone + Cabazitaxel + 16 (3.1) Olaparib 9 (4.8) 8 (10.0) Docetaxel Carboplatin 1 Olaparib 16 (3.1) Lutetium-177 7 (3.7) Lutetium-177 6 (7.5) Abiraterone + Sipuleucel-T 15 (2.9) 4 (2.1) Radium-223 5 (6.3) Sipuleucel-T Other..."

Clinical • HEOR • Metastases • P3 data • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Circulating Tumour DNA Genomic Correlatives in mCRPC Treated with LuPSMA or Cabazitaxel from the Randomised Phase II TheraP Trial (ANZUP 1603) (PCF 2025) - No abstract available

Circulating tumor DNA • Clinical • P2 data • Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer

Comparative efficacy and safety of cabazitaxel versus other taxanes: a systematic review and meta-analysis. (PubMed, Syst Rev) - "Cabazitaxel shows no OS or PFS advantage over other taxanes and higher toxicity. 20 mg/m2 is safer than 25 mg/m2. It remains an option when other taxanes are contraindicated, not tolerated, or exhausted, with possible benefit over non-taxanes in mCRPC and worse outcomes in head and neck squamous cell carcinoma (HNSCC). Dosing and monitoring should be individualized. Further research should refine patient selection, dosing, and toxicity management."

Clinical • Journal • Retrospective data • Review • Breast Cancer • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hematological Disorders • Neutropenia • Oncology • Prostate Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck